Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223424 · ClinicalTrials.gov registry record · Phase 2
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
A Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Diwakar Davar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
- 1
- Study location
NCT07223424: Recruiting Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Diwakar Davar.
NCT07223424 is a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by Diwakar Davar. The registered enrollment target is 480 participants, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223424, a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by Diwakar Davar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Primary Outcome
The proportion of patients with locally advanced or advanced/metastatic solid tumors who prefer SC to IV nivolumab.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG nivolumab
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2030-11-30 |
| Phase | Phase 2 |
What NCT07223424 shows while recruiting
NCT07223424 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (26% lower).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT07223424 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07223424 about?
NCT07223424 is a clinical study titled "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy". The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
What is the current status of trial NCT07223424?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2025-11-04. Estimated completion is 2030-11-30.
What conditions does trial NCT07223424 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Cervical Cancer, Hepatocellular Carcinoma, Esophageal Cancer.
What interventions are being tested in trial NCT07223424?
The interventions under investigation include: pembrolizumab (DRUG), nivolumab (DRUG).
Who is sponsoring clinical trial NCT07223424?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223424 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07223424's enrollment target sits among peer trials
480 82nd of 454 higher than 372 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI